일요일, 3월 22, 2026
HomeMedical NewsThe efficacy and security of thymosin α1 for sepsis (TESTS): multicentre, double...

The efficacy and security of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo managed, part 3 trial


A few of the knowledge on this paper by Wu and colleagues (BMJ 2025;388:e082583, doi:10.1136/bmj-2024-082583, revealed 15 January 2025) have been up to date. Disruptions to scientific service throughout the covid-19 pandemic affected the info verification course of at a number of the trial centres resulting in inaccurate knowledge being entered within the trial database. Though these errors have been subsequently corrected, the ends in the revealed paper have been based mostly on the outdated knowledge. The article and PDF have since been corrected.

Survival knowledge

9 individuals (9/1106) have been thought of as losses to follow-up within the database throughout the covid-19 pandemic. After the pandemic, survival knowledge have been obtained for these individuals, and all analyses besides the survival analyses have been up to date. After correction, the hazard ratio for the first final result (28 day mortality) modified to 0.97 (0.76 to 1.24) [not 0.99 (0.77 to 1.27)] and for 90 day mortality to 0.95 (0.77 to 1.17) [not 0.94 (0.76 to 1.16)].

Immunological knowledge

The unique dataset included errors for lymphocyte counts in 35 individuals (35/1106; 3%). Consequently, minor amendments have been made to supplementary desk S8 and determine S2.

Information sharing

The info sharing assertion has been revised.

RELATED ARTICLES
RELATED ARTICLES

Most Popular